Presentation is loading. Please wait.

Presentation is loading. Please wait.

Sample timeline for disaster preparation and response.

Published byHilary Stanley Modified over 5 years ago

Similar presentations

Presentation on theme: "Sample timeline for disaster preparation and response."— Presentation transcript:

1 Sample timeline for disaster preparation and response.
Sample timeline for disaster preparation and response. On the top row are the tasks for dialysis patients and dialysis facilities; on the bottom row are the tasks for ESRD networks, KCERC (Kidney Community Emergency Response Coalition), and emergency responders. The sample timeline gives only approximate days for particular activities; the specific timing will be adjusted to meet local conditions, anticipated damage, local regulations, and emergency plans. Disasters such as hurricanes, floods, ice and snow storms, and wildfires are to some extent predictable, although the number of days of advance warning will vary. ANNA, American Nephrology Nurses Association; CMS, Centers for Medicare and Medicaid Services; EOC, emergency operations center; JFO, joint field office. Jeffrey B. Kopp et al. CJASN 2007;2: ©2007 by American Society of Nephrology

Download ppt "Sample timeline for disaster preparation and response."

Similar presentations

Recovery Operations.

Recovery Operations.
Overview of Climate Resilience in Transportation Planning October, 2017 Savannah, GA Jill Stark, FHWA, Office of Planning.

Overview of Climate Resilience in Transportation Planning October, 2017 Savannah, GA Jill Stark, FHWA, Office of Planning.
Pneumococcal pneumonia vaccinations, by unit affiliation.

Pneumococcal pneumonia vaccinations, by unit affiliation.
Among Medicare beneficiaries >65 years old with a index hospitalization at the time of dialysis initiation, use of post-acute SNF care was common. Among.

Among Medicare beneficiaries >65 years old with a index hospitalization at the time of dialysis initiation, use of post-acute SNF care was common. Among.
Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.

Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.
Figure 1.17 of the 2016 US Renal Data System Annual Data Report, Volume 2, chapter 1 showing the trends in the number of patients with incident ESRD (in.

Figure 1.17 of the 2016 US Renal Data System Annual Data Report, Volume 2, chapter 1 showing the trends in the number of patients with incident ESRD (in.
Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.

Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.
Volume 75, Issue 11, Pages (June 2009)

Volume 75, Issue 11, Pages (June 2009)
Adjusted rate ratios of hospital days and admissions for blacks and Hispanics compared with whites by age group. Adjusted rate ratios of hospital days.

Adjusted rate ratios of hospital days and admissions for blacks and Hispanics compared with whites by age group. Adjusted rate ratios of hospital days.
Conceptual model of the natural history of diabetic kidney disease.

Conceptual model of the natural history of diabetic kidney disease.
Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.

Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.
Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.
Three-year cumulative incidence of a gout diagnosis presented by level of kidney function and sex. Three-year cumulative incidence of a gout diagnosis.

Three-year cumulative incidence of a gout diagnosis presented by level of kidney function and sex. Three-year cumulative incidence of a gout diagnosis.
Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.

Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.
Box plots showing the relative difference in distribution of mtDNA copy number per cell between patients with ESRD and healthy control subjects frequency.

Box plots showing the relative difference in distribution of mtDNA copy number per cell between patients with ESRD and healthy control subjects frequency.
ROC curves. ROC curves. The four plots represent the ROC curves from the following four prediction models for day 3 AKI: RAI (A), NGAL and RAI (B), MMP-8.

ROC curves. ROC curves. The four plots represent the ROC curves from the following four prediction models for day 3 AKI: RAI (A), NGAL and RAI (B), MMP-8.
Association of HD treatment with polysomnographic parameters and EDS after adjustment for age, gender, and BMI. Error horizontal lines represent the 95%

Association of HD treatment with polysomnographic parameters and EDS after adjustment for age, gender, and BMI. Error horizontal lines represent the 95%
Representative transaxial thin computed tomography (CT) sections at mid, mid-low, and low levels of the heart from a control subject (left) showing normal.

Representative transaxial thin computed tomography (CT) sections at mid, mid-low, and low levels of the heart from a control subject (left) showing normal.
Drug levels during the course of a dosing interval.

Drug levels during the course of a dosing interval.
(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E

(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E

Similar presentations

Ads by Google